“It is very gratifying to have now secured the capital that Lipidor needs to carry out the Phase III study. We have had strong support from our main shareholders and would like to take the opportunity to thank all existing and new shareholders who supported us. Lipidor is now facing the most pivotal year in our company’s history and we look forward to keeping you updated on our progress towards study results”, says Ola Holmlund, CEO Lipidor.

“LSIF is happy to have become a major shareholder in Lipidor. With the company having identified and addressed the issue in the failed Phase III trial, Lipidor and the psoriasis patients deserves a new trial, and we believe the chances of success in this new trial to be very promising,” says Jan Poulsen, CEO Life Science Invest Fund.

The subscription period of the Rights Issue ended on June 12, 2024, and the preliminary outcome shows that 96,145,618 units, corresponding to approximately SEK 19.2 million or approximately 33.2 percent of the Rights Issue, were subscribed for through the exercise of unit rights. An additional 11,224,600 units were subscribed for without the exercise of unit rights, corresponding to approximately SEK 2.2 million or approximately 3.9 percent of the Rights Issue. In total, 107,370,218 units were subscribed for with and without the exercise of unit rights, corresponding to approximately SEK 21.5 million or approximately 37.1 percent of the Rights Issue. Consequently, a total of 82,428,237 units, corresponding to approximately SEK 16.5 million and approximately 28.4 percent of the Rights Issue, are preliminary subscribed for through the fulfilment of guarantee undertakings. Based on the preliminary outcome in the Rights Issue the Company will receive approximately SEK 38.0 million before issuing costs.

Units subscribed for without the exercise of unit rights will be allocated according to the principles set out in the EU Growth Prospectus published by the Company on May 24, 2024. In the event that investors who have subscribed in the Rights Issue are subject to notification under The Screening of Foreign Direct Investments Act (2023:560), the allocation to these investors may under certain circumstances be delayed. Notification of allocation of units subscribed for without the support of unit rights will be sent shortly after the final outcome in the Rights Issue has been announced to those who have been allocated units through a settlement note. Shareholders registered with a nominee will be notified of their allocation in accordance with the nominee’s procedures. Each unit in the Rights Issue consists of four (4) shares and one (1) Warrant. The final outcome in the Rights Issue is estimated to be announced tomorrow, 13 June 2024.

Share capital and number of shares

Based on the preliminary outcome in the Rights Issue, the Rights Issue will entail that the share capital in the Company increases by SEK 37,959,691, from SEK 1,448,843.15 to SEK 39,408,534.15, through the issuance of 759,193,820 shares. The number of shares thus increases from 28,976,863 to 788,170,683 shares. The dilution amounts to 96.3 percent. Upon full exercise of all Warrants, based on the preliminary outcome in the Rights Issue, the share capital will increase by an additional SEK 9,489,922.75, to SEK 48,898,456.90, through the issuance of 189,798,455 shares. The number of shares thereby increases from to 977,969,138 shares, corresponding to an additional dilution of approximately 19.4 percent.

Advisors

Lipidor has mandated Penser by Carnegie, Carnegie Investment Bank AB (publ) and Fredersen Advokatbyrå AB as financial and legal advisors respectively in connection with the Rights Issue.